AbbVie will commit less capital towards experimental medicines for psychiatric disease, CEO Robert Michael said at an ...
The FDA has approved Cobenfy, a new drug to treat people with schizophrenia that comes with fewer side effects.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback